Semaglutide delays gastric emptying, which can affect absorption of some oral medications
GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Apoptosis in cardiac tissue was confirmed via terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay and supported by expression of pro-apoptotic protein BAX and decreased levels of PARP, caspase-3, and Bcl-2
These medications slow the stomachs emptying process, prolonging the feeling of satiety after meals
However, no clinical trials have evaluated this combination, and any multi-peptide or peptide-plus-GLP-1 protocol should be managed by a practitioner who can monitor labs, adjust doses, and watch for unexpected interactions
In the open-label phase of this trial, pain improvement continued